In March 2022, the U.S. Food and Drug Administration (FDA) granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. Myopia is also known as nearsightedness or the need for distance vision correction.